MINK THERAPEUTICS INC
INKTNASDAQ🏆 #3316 by market capEarnings Aug 13 · PreUS Equity
$777.49▼ $37.55 (−4.83%)
Simulated price1h—
24h▼ 4.8%
7d—
14d—
30d—
1y—
🏦Market Cap
$56M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
50
Weak
No chart data available for INKT.
Trading Snapshot
- Day Range
- $772.29 – $790.43
- 52-Week Range
- $8.48 – $18.17
- Volume
- $6.10B
- Avg Volume
- $6.92B
- Shares Outstanding
- 5.0M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.84
- Dividend Yield
- —
Why Investors Own INKT
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$7M▲ +29.4% YoY
Gross Margin (TTM)
77.8%▲ +2.4% YoY
Operating Income (TTM)
$2M▲ +29.4% YoY
Free Cash Flow (TTM)
$2M▲ +29.4% YoY
About MINK THERAPEUTICS INC
A company profile for MINK THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
50/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
Latest News & Updates
🚀
MarketWatch·2h ago
MINK THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift INKT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
MINK THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.